treatment options for relapsed-refractory dlbcl
Published 4 years ago • 260 plays • Length 2:41Download video MP4
Download video MP3
Similar videos
-
6:43
current treatment approach to relapsed/refractory dlbcl
-
4:31
using novel therapy in relapsed-refractory dlbcl
-
5:47
choosing therapy for relapsed/refractory fl
-
3:16
cd19-targeted mabs in relapsed/refractory dlbcl
-
2:16
study go29365 in relapsed-refractory dlbcl
-
37:22
eha 2024 recap: optimizing the relapsed/refractory cll treatment pathway
-
3:31
nccn guidelines for relapsed/refractory mcl
-
6:08
relapsed/refractory dlbcl treatment landscape
-
0:48
car t cell options for relapsed/refractory dlbcl
-
4:52
therapy for relapsed or refractory mcl
-
1:31
long-term outcomes with tafasitamab plus lenalidomide for r/r dlbcl
-
6:51
treating relapsed/refractory dlbcl
-
4:32
how is relapsed/refractory dlbcl treated?
-
2:15
vipor: a multi-targeted therapy for the treatment of r/r dlbcl
-
4:53
follicular lymphoma: selecting therapy at relapse
-
4:58
choosing second-line therapy for relapsed/refractory fl
-
3:56
treatment approaches to relapsed/refractory fl
-
1:12
evaluating the role of car t-cell therapy in relapsed/refractory dlbcl
-
3:41
treatment options for relapsed follicular lymphoma